AP 304
Alternative Names: AP-304Latest Information Update: 15 Sep 2022
At a glance
- Originator Shanghai Alebund Pharmaceuticals
- Class
- Mechanism of Action Polycystic kidney disease 2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autosomal dominant polycystic kidney disease
Most Recent Events
- 22 Aug 2022 Preclinical trials in Autosomal dominant polycystic kidney disease in China (unspecified route) before August 2022 (Shanghai Alebund Pharmaceuticals website, August 2022)
- 22 Aug 2022 Shanghai Alebund Pharmaceuticals plans to initiate phase I trial in Autosomal Dominant Polycystic Kidney Disease by 2024 (Shanghai Alebund Pharmaceuticals pipeline, August 2022)